Fundraising Fox

Oyster Point Pharma, Inc.

San Francisco, US · Founded 2015 · Delaware corporation · 3 known investors

oysterpointrx.com ↗

Viatris develops and manufactures pharmaceutical products including generic medicines, branded pharmaceuticals, and over-the-counter therapies for global markets. The company focuses on making medicines more affordable and accessible while maintaining supply chain resilience.

BiotechHealthtechin /Viatris@viatrisinc

Founders & leadership

DM
D. Michael AckermannDirector
MA
Mark A. MurrayExecutive Officer, Director
WJ
William J LinkDirector
JN
Jeffrey NauExecutive Officer, Director
AB
Ali BehbahaniDirector

Investors · 3

Flying L Partners
New Enterprise Associates (NEA)reportedMenlo Park · $200K – $40Mvia Ali Behbahani · board
Versant Venture AIV HoldingsreportedSan Francisco

Reported raises · per SEC filings

Form D private placements
▶$85MraisedFeb 2019 · 7 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • William J LinkDirector
  • D. Michael AckermannDirector
  • Clare OzawaDirector
  • Benjamin TsaiDirector
  • Ali BehbahaniDirector
  • Jeffrey NauExecutive Officer, Director
  • Mark A. MurrayExecutive Officer, Director
Offering amount
$93M
Amount sold
$85M
First sale
Feb 2019
Incorporated
Corporation, Delaware, 2015
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$28.6MraisedOct 2017 · 8 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • D. Michael AckermannDirector
  • Mark A. MurrayExecutive Officer, Director
  • William J LinkDirector
  • Jeffrey NauExecutive Officer, Director
  • Ali BehbahaniDirector
Offering amount
$43.1M
Amount sold
$28.6M
First sale
Oct 2017
Incorporated
Corporation, Delaware, 2015
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.